November 2022
171 articles-
Nov 30 · 08:11Biotechnology Daily
Seres one step closer to bringing first oral microbiome therapy to market as FDA mulls approval
-
Nov 30 · 08:10Biotechnology Daily
Clario highlights 3 areas where AI can support patients in decentralized trials
-
Nov 30 · 08:08Biotechnology Daily
Merck KGaA, with phase 3 data on the horizon, showcases durability of evobrutinib in multiple sclerosis
-
Nov 30 · 08:07Biotechnology Daily
PacBio unveils its first short-read DNA sequencer plus a long-read system upgrade
-
Nov 30 · 08:05Bio Business News
Boston Scientific picks up slowing sales growth, edges out forecasts with $3.2B in Q3
-
Nov 30 · 08:04Bio Business News
Treading where Roche and Sanofi failed, AstraZeneca scores breast cancer wins for AKT and SERD drugs
-
Nov 30 · 08:03Bio Business News
Symeres acquires Exemplify BioPharma in 2nd US buy this year
-
Nov 30 · 08:02Bio Business News
Recursion reprioritizes, dumping rare disease asset while raking in $150M
-
Nov 29 · 05:19Biotechnology Daily
Ipsen gets new FDA data request on its tumultuous rare disease med, delaying advisory meeting
-
Nov 29 · 05:17Biotechnology Daily
'Think beyond the label': How AI developers can build patient trust and improve transparency
-
Nov 29 · 05:16Biotechnology Daily
GSK's ViiV gives early look at HIV broadly neutralizing antibody's power, eyes long-acting combo trial
-
Nov 29 · 05:10Biotechnology Daily
Overeating sweet treats? Scientists discover what drives this desire
-
Nov 29 · 05:08Bio Business News
Verily to build data-powered registry of IBD patients to accelerate Crohn's, colitis research
-
Nov 29 · 05:06Bio Business News
GSK axes Lyell cell therapy, passes programs to Adaptimmune
-
Nov 29 · 05:03Bio Business News
Biogen insists Eisai relationship 'solid' as questions remain over lecanemab commercialization
-
Nov 29 · 04:59Bio Business News
Novartis stops liver transplant program after Astellas drug beats its CD40 prospect in phase 2
-
Nov 29 · 04:12Market Watch
Bilibili's Third-Quarter Loss Expected to Narrow
-
Nov 28 · 02:02Biotechnology Daily
Alpine bails on phase 1 cancer asset after 2nd patient death reported in Keytruda combo study
-
Nov 28 · 02:01Biotechnology Daily
Tricida's shares plunge as phase 3 fail seals fate of FDA-rejected kidney disease drug
-
Nov 28 · 01:59Biotechnology Daily
FDA clears Philips AI for making CT-like images from head and neck MRI scans
-
Nov 28 · 01:57Biotechnology Daily
BioIntelliSense expands in-hospital monitoring for patient-tracking wearable with AlertWatch buy
-
Nov 28 · 01:55Bio Business News
Astellas continues gene therapy push with $50M for stake in Taysha, options on 2 CNS assets
-
Nov 28 · 01:53Bio Business News
Medtronic to spin out respiratory, patient monitoring divisions amid flagging ventilator sales
-
Nov 28 · 01:51Bio Business News
Philips cuts 4,000 jobs, with more restructuring on the way, amid slipping sales and rising costs